Bolt Biotherapeutics (DE:6LP0)
FRANKFURT:6LP0
6LP0 Stock Chart & Stats
€5.18
--
Market closed
€5.18
--
Day’s Range― - ―
52-Week Range€4.99 - €5.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€7.66M
Enterprise Value€20.79M
Total Cash (Recent Filing)€22.89M
Total Debt (Recent Filing)€22.31M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 12, 2026EPS Estimate
-2.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.89
Shares Outstanding1,921,567
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.29Price Target Upside368.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-12.39
Revenue Forecast (FY)€1.30M
Bulls Say, Bears Say
Bulls Say
Proprietary Boltbody PlatformBolt's Boltbody platform is a structural competitive asset: directing immune activation inside tumors can differentiate efficacy and safety profiles. A working platform supports multiple programs, enables licensing/partnerships, and provides durable upside if translational success scales across indications.
Diverse Clinical-stage PipelineMaintaining multiple investigational candidates spreads development risk and increases the probability of a successful asset. A multi-program pipeline supports sustained R&D activity, potential partnering/licensing opportunities, and a longer-term pathway to commercial revenue if any candidate advances to approval.
Improved Gross MarginsMaterial improvement in gross margins suggests the company has strengthened product economics or reduced COGS, which is important for eventual commercialization. Strong unit economics are a durable advantage, increasing potential long-term profitability if pipeline products reach market.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicate ongoing cash consumption to fund R&D and operations. Over 2–6 months this creates structural dependence on external financing or partnerships, raising dilution risk and potentially constraining development timelines and program choices.
Very Small, Declining Revenue BaseLow and shrinking revenue means Bolt lacks commercial sales and is dependent on collaborations, milestones, or financing. This weak top-line reduces internal funding flexibility and heightens reliance on successful clinical outcomes and external capital to sustain long-term development programs.
Rising Leverage And Contracted EquityHigher leverage and shrinking equity weaken the balance sheet cushion and increase refinancing risk. For a clinical-stage biotech, this structural deterioration reduces financial flexibility, may raise borrowing costs, and increases the likelihood of dilutive financings to sustain operations.
Bolt Biotherapeutics News
6LP0 FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was €4.99 and its highest was €5.78 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is €7.66M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 68 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on May 12, 2026. The company reported -€3.711 earnings per share for the quarter, missing the consensus estimate of -€2.454 by -€1.257.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics does not currently pay dividends.
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -2.92.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,921,567 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -€3.711 in its last earnings report, missing expectations of -€2.454. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in DE:6LP0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
6LP0 Stock 12 Month Forecast
Average Price Target
€24.29
▲(368.85% Upside)
Technical Analysis
Eterna Therapeutics
―
Xenetic Biosciences
―
Mustang Bio
―
Lyra Therapeutics
―
IN8bio
―
Options Prices
Currently, No data available
---